|
BE637389A
(pm)
*
|
1962-09-13 |
|
|
|
|
GB1560274A
(en)
*
|
1977-02-28 |
1980-02-06 |
Ici Ltd |
Phenylbut 1-ene derivatives having antiostrogenicactivity
|
|
DE2860900D1
(en)
*
|
1977-08-22 |
1981-11-05 |
Ici Plc |
Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them
|
|
DE3046719C2
(de)
*
|
1980-12-11 |
1983-02-17 |
Klinge Pharma GmbH, 8000 München |
1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
|
|
ATE25515T1
(de)
*
|
1983-05-24 |
1987-03-15 |
Bristol Myers Co |
Verfahren zur umwandlung von 1,2-diphenyl-1-(4-(2-dimethylamino-ethoxy)-phen l>-1-buten-e-isomeren zu tamoxifen-hydrochlorid.
|
|
US4760053A
(en)
*
|
1984-08-02 |
1988-07-26 |
Fernand Labrie |
Combination therapy for selected sex steroid dependent cancers
|
|
US4666885A
(en)
*
|
1985-02-08 |
1987-05-19 |
Fernand Labrie |
Combination therapy for treatment of female breast cancer
|
|
US4775660A
(en)
*
|
1984-08-02 |
1988-10-04 |
Fernand Labrie |
Treatment of breast cancer by combination therapy
|
|
US4806685A
(en)
*
|
1985-08-05 |
1989-02-21 |
Gyogyszerkutato Inteezet/Pharmaceutical Research Institute |
1,1,2-triphenylpropane and -propene derivatives
|
|
GB8604528D0
(en)
*
|
1986-02-24 |
1986-04-03 |
Ici Plc |
Therapeutic agents
|
|
CA1289570C
(en)
*
|
1986-06-16 |
1991-09-24 |
Tetsuji Asao |
1,1,2-triaryl-1-alkene derivatives
|
|
ES2044860T3
(es)
*
|
1987-04-21 |
1994-01-16 |
Heumann Pharma Gmbh & Co |
Estables aductos con disolventes de z-1-(p-beta-di-metil-amino-etoxi-fenil)-1-(p-hidroxi-fenil)-2-fenil-but-1-eno.
|
|
DE3736682A1
(de)
*
|
1987-10-29 |
1989-05-11 |
Klinge Co Chem Pharm Fab |
Verfahren zur herstellung von trans-1,1,2-triphenyl-but-1-en-derivaten
|
|
US4895715A
(en)
*
|
1988-04-14 |
1990-01-23 |
Schering Corporation |
Method of treating gynecomastia
|
|
US5204337A
(en)
*
|
1988-10-31 |
1993-04-20 |
Endorecherche Inc. |
Estrogen nucleus derivatives for use in inhibition of sex steroid activity
|
|
US5364847A
(en)
*
|
1989-03-10 |
1994-11-15 |
Endorecherche |
Inhibitors of sex steroid biosynthesis and methods for their production and use
|
|
ZA924811B
(en)
*
|
1991-06-28 |
1993-12-29 |
Endorecherche Inc |
Controlled release systems and low dose androgens
|
|
US6515009B1
(en)
|
1991-09-27 |
2003-02-04 |
Neorx Corporation |
Therapeutic inhibitor of vascular smooth muscle cells
|
|
US5811447A
(en)
|
1993-01-28 |
1998-09-22 |
Neorx Corporation |
Therapeutic inhibitor of vascular smooth muscle cells
|
|
US5446203A
(en)
*
|
1992-08-25 |
1995-08-29 |
New York University |
Synthesis of haloenones and aryl or alkyl substituted enones or alkenes
|
|
US5770609A
(en)
*
|
1993-01-28 |
1998-06-23 |
Neorx Corporation |
Prevention and treatment of cardiovascular pathologies
|
|
US6251920B1
(en)
|
1993-05-13 |
2001-06-26 |
Neorx Corporation |
Prevention and treatment of cardiovascular pathologies
|
|
US5354861A
(en)
*
|
1992-11-04 |
1994-10-11 |
National University Of Singapore |
2-(benzyl)-3-arylbenzofurans as antitumour and hypocholesterolemic agents
|
|
US6491938B2
(en)
|
1993-05-13 |
2002-12-10 |
Neorx Corporation |
Therapeutic inhibitor of vascular smooth muscle cells
|
|
US6197789B1
(en)
|
1995-06-07 |
2001-03-06 |
Neorx Corporation |
Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
|
|
WO1994026303A1
(en)
*
|
1993-05-13 |
1994-11-24 |
Neorx Corporation |
Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
|
|
EP0635264B1
(en)
*
|
1993-06-24 |
1997-09-10 |
Eli Lilly And Company |
Antiestrogenic 2-phenyl-3-aroylbenzothiophenes as hypoglycemic agents
|
|
GB9326255D0
(en)
*
|
1993-12-23 |
1994-02-23 |
Roussel Lab Ltd |
Medical device for the prevention and treatment of cancer
|
|
US5650425A
(en)
*
|
1994-04-04 |
1997-07-22 |
Pharmos Corporation |
Permanently ionic derivatives of steroid hormones and their antagonists
|
|
US5681835A
(en)
*
|
1994-04-25 |
1997-10-28 |
Glaxo Wellcome Inc. |
Non-steroidal ligands for the estrogen receptor
|
|
PL181304B1
(pl)
|
1994-07-22 |
2001-07-31 |
Lilly Co Eli |
Preparat farmaceutyczny do hamowania zmniejszania masy kosci PL PL PL PL PL PL PL PL PL PL
|
|
DE19526146A1
(de)
*
|
1995-07-07 |
1997-01-09 |
Schering Ag |
Triphenylethylene, Verfahren zu deren Herstellung, diese Triphenylethylene enthaltene pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
|
|
WO1997026234A1
(en)
|
1996-01-20 |
1997-07-24 |
Bradford University |
Tamoxifen and analogues thereof
|
|
HN1996000101A
(es)
|
1996-02-28 |
1997-06-26 |
Inc Pfizer |
Terapia combinada para la osteoporosis
|
|
US6083990A
(en)
|
1997-04-02 |
2000-07-04 |
Pharmos Corporation |
Enhanced anti-angiogenic activity of permanently charged derivatives of steroid hormones
|
|
JP2001511182A
(ja)
*
|
1997-02-09 |
2001-08-07 |
ファーモス コーポレイション |
ステロイドホルモンの永久に荷電された誘導体の増進された抗血管形成誘導活性
|
|
BR9807271A
(pt)
*
|
1997-02-27 |
2000-05-23 |
Pharmacia & Upjohn Spa |
Tamoxifeno como terapia para reduzir diarréia induzida por cloridrato de irinotecano
|
|
GB9715479D0
(en)
*
|
1997-07-23 |
1997-10-01 |
Univ Bradford |
Tamoxifen and analogues thereof
|
|
BR9811946A
(pt)
|
1997-08-15 |
2000-08-22 |
Univ Duke |
Método para prevenção ou tratamento de distúrbios e doenças dependentes de estrogênio
|
|
UA66370C2
(en)
|
1997-12-16 |
2004-05-17 |
Lilly Co Eli |
Arylpiperazines having activity to setotonin 1 receptors
|
|
GB9824207D0
(en)
*
|
1998-11-04 |
1998-12-30 |
Zeneca Ltd |
Neurological disorders
|
|
TW593256B
(en)
|
1999-11-16 |
2004-06-21 |
Hormos Medical Oy Ltd |
Triphenylalkene derivatives and their use as selective estrogen receptor modulators
|
|
US20020013327A1
(en)
*
|
2000-04-18 |
2002-01-31 |
Lee Andrew G. |
Compositions and methods for treating female sexual dysfunction
|
|
GB0012291D0
(en)
*
|
2000-05-23 |
2000-07-12 |
Astrazeneca Ab |
Pharmaceutical combination
|
|
US6613083B2
(en)
|
2001-05-02 |
2003-09-02 |
Eckhard Alt |
Stent device and method
|
|
RU2188000C1
(ru)
*
|
2001-09-27 |
2002-08-27 |
Нестерук Владимир Викторович |
Лекарственное средство на основе тамоксифена
|
|
ATE343376T1
(de)
*
|
2002-03-20 |
2006-11-15 |
Elan Pharma Int Ltd |
Nanopartikelzusammensetzungen von angiogeneseinhibitoren
|
|
NZ538498A
(en)
*
|
2002-07-30 |
2009-02-28 |
Childrens Medical Center |
Compositions of ezetimibe and methods for the treatment of cholesterol-associated benign and malignant tumors
|
|
US7332525B2
(en)
*
|
2003-01-17 |
2008-02-19 |
Castle Erik P |
Method of treatment of prostate cancer and composition for treatment thereof
|
|
US20040248989A1
(en)
*
|
2003-06-05 |
2004-12-09 |
Risto Santti |
Method for the treatment or prevention of lower urinary tract symptoms
|
|
RU2331425C2
(ru)
*
|
2003-09-19 |
2008-08-20 |
Висконсин Эламнай Рисерч Фаундейшн (ВАРФ) |
Фармацевтические композиции и способы, включающие комбинации производных 2-алкилиден-19-нор-витамина d и агониста/антагониста эстрогенов
|
|
BRPI0416639A
(pt)
|
2003-11-19 |
2007-01-16 |
Metabasis Therapeutics Inc |
tiromiméticos contendo fósforo
|
|
EP1729793B1
(en)
|
2004-03-02 |
2015-07-22 |
Acceleron Pharma Inc. |
Alk7 and myostatin inhibitors for muscle wasting disorders
|
|
US20050203086A1
(en)
*
|
2004-03-04 |
2005-09-15 |
Pfizer Inc. |
Methods of treatment using an EP2 selective receptor agonist
|
|
ATE439347T1
(de)
*
|
2004-11-23 |
2009-08-15 |
Warner Lambert Co |
7-(2h-pyrazol-3-yl)-3,5-dihydroxy-heptansäure- derivate als hmg-co-a-reductase-inhibitoren zur behandlung von lipidemia
|
|
CA2594477C
(en)
|
2005-01-21 |
2016-07-12 |
Astex Therapeutics Limited |
Pharmaceutical compounds
|
|
NZ565654A
(en)
|
2005-07-18 |
2010-10-29 |
Bipar Sciences Inc |
Use of iodonitrobenzamide compounds for the treatment of ovarian cancer
|
|
US7741317B2
(en)
|
2005-10-21 |
2010-06-22 |
Bristol-Myers Squibb Company |
LXR modulators
|
|
US7888376B2
(en)
|
2005-11-23 |
2011-02-15 |
Bristol-Myers Squibb Company |
Heterocyclic CETP inhibitors
|
|
AU2007252991B2
(en)
|
2006-05-22 |
2012-08-02 |
Hormos Medical Ltd. |
Selective estrogen receptor modulators or aromatase inhibitors for treating chronic nonbacterial prostatitis
|
|
EP2034984A4
(en)
|
2006-06-02 |
2013-03-06 |
Pear Tree Women S Health Care |
PROCESS FOR TREATING ATROPHIC VAGINITIS
|
|
US20100160442A1
(en)
*
|
2006-07-18 |
2010-06-24 |
Ossovskaya Valeria S |
Formulations for cancer treatment
|
|
US8883790B2
(en)
|
2006-10-12 |
2014-11-11 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
|
US8916552B2
(en)
|
2006-10-12 |
2014-12-23 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
|
US8404896B2
(en)
|
2006-12-01 |
2013-03-26 |
Bristol-Myers Squibb Company |
N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases
|
|
CN101678107A
(zh)
|
2007-08-03 |
2010-03-24 |
萨米特公开有限公司 |
用于治疗杜兴型肌营养不良的药物组合物
|
|
GB0715087D0
(en)
|
2007-08-03 |
2007-09-12 |
Summit Corp Plc |
Drug combinations for the treatment of duchenne muscular dystrophy
|
|
US8372887B2
(en)
|
2007-10-16 |
2013-02-12 |
Repros Therapeutics Inc. |
Trans-clomiphene for metabolic syndrome
|
|
WO2010093601A1
(en)
|
2009-02-10 |
2010-08-19 |
Metabasis Therapeutics, Inc. |
Novel sulfonic acid-containing thyromimetics, and methods for their use
|
|
US20140378422A1
(en)
|
2012-01-31 |
2014-12-25 |
Novartis Ag |
Combination of a RTK inhibitor with an anti-estrogen and use thereof for the treatment of cancer
|
|
JP2015508825A
(ja)
|
2012-02-29 |
2015-03-23 |
レプロス セラピューティクス インコーポレイティド |
アンドロゲン欠乏症を治療するための併用療法
|
|
EP3296300B1
(en)
|
2012-03-05 |
2019-08-07 |
Xavier University |
Boron-based 4-hydroxytamoxifen and endoxifen prodrugs as treatment for breast cancer
|
|
CN103992234B
(zh)
*
|
2014-06-11 |
2016-05-18 |
扬子江药业集团江苏海慈生物药业有限公司 |
一种枸橼酸他莫昔芬e异构体的制备方法
|
|
JP7048505B2
(ja)
|
2015-11-10 |
2022-04-05 |
パラクリン セラピューティクス エービー |
Pdgf-cc阻害剤および抗エストロゲン剤によるer陰性乳癌の処置
|
|
US20190183870A1
(en)
|
2016-01-05 |
2019-06-20 |
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services |
Combination of histone deacetylase inhibitor and immunotherapy
|
|
WO2017136342A1
(en)
|
2016-02-02 |
2017-08-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Fulvestrant for inducing immune-mediated cytotoxic lysis of cancer cells
|
|
US12059403B2
(en)
|
2016-08-04 |
2024-08-13 |
University Of Iowa Research Foundation |
Use of SWELL1 inhibitors and modulators to treat type 2 diabetes and obesity
|
|
CA3032153A1
(en)
|
2016-08-19 |
2018-02-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Selective estrogen-receptor modulators (serms) confer protection against photoreceptor degeneration
|
|
KR20200138714A
(ko)
|
2018-02-21 |
2020-12-10 |
에이아이 테라퓨틱스, 인코포레이티드 |
아필리모드 및 글루타메이트성 작용제를 사용한 병용 요법
|
|
CN114514021A
(zh)
*
|
2019-06-10 |
2022-05-17 |
爱荷华大学研究基金会 |
用于治疗非酒精性脂肪性肝病、免疫缺陷、男性不育症和血管疾病的swell1调节剂
|
|
CN114133334B
(zh)
*
|
2021-11-09 |
2024-07-19 |
北京京丰制药(山东)有限公司 |
枸橼酸他莫昔芬的工业化制备工艺
|
|
EP4230196A1
(en)
|
2022-02-21 |
2023-08-23 |
Som Innovation Biotech, S.A. |
Compounds for use in the treatment of dystrophinopathies
|
|
EP4311546A1
(en)
|
2022-07-26 |
2024-01-31 |
Dynacure |
Combination therapy for myopathies
|
|
WO2024254189A1
(en)
|
2023-06-06 |
2024-12-12 |
Daré Bioscience, Inc. |
Compositions and methods for treating vulvar and vaginal atrophy (vva)
|